05. The data are presented within the text,
Tables, and Figures as mean ± SD. Results Overview and adverse effects All subjects successfully completed all aspects of this study. Selonsertib Compliance to capsule intake was 99.9 ± 7.6, considering all subjects. No serious adverse events were observed during this study. However, one subject in the 1.5 grams/day MSM group reported mild nausea during his last visit. Heart rate and blood pressure responded as expected to acute exercise (these variables increased slightly and returned to baseline rapidly) and were not differently influenced by either dosage of MSM (p > 0.05). Recovery and performance data Regarding muscle soreness, the 1.5 grams/day group experienced a 0.5 point greater reduction in muscle
soreness during the TEW-7197 PHA-848125 mouse post intervention visit as compared to pre intervention, and the 3.0 grams/day group experienced a 1.5 point greater reduction in soreness during the post intervention visit as compared to pre intervention. This 1.0 point difference in baseline-adjusted muscle soreness from two hours post-exercise to 48 hours post-exercise approached statistical significance (p = 0.080), suggesting a dose-related improvement. The Cohen’s D value for the outcome of muscle soreness was 0.28 and the Pearson’s r value (effect size) was 0.14. Muscle soreness data are presented in Figure 1. Figure 1 Muscle soreness of 8 healthy men assigned to MSM. Blue Open Circle = 1.5 grams/day; Red Filled Circle = 3.0 grams/day. Data are presented as change Rapamycin chemical structure from baseline (Δ from BL) on y-axis; Visit 2 is pre intervention (prior to MSM supplementation), Visit 3 is post intervention (following MSM supplementation); Visit 1 included the screening visit. Note: There were statistically significant increases in muscle soreness with and without MSM at the two hour post-exercise time (p= 0.021 and p=0.007, respectively); The 1.5 grams/day group experienced a 0.5 point greater reduction in
muscle soreness during Visit 3 (post intervention) as compared to Visit 2 (pre intervention), and the 3.0 grams/day group experienced a 1.5 point greater reduction in soreness during Visit 3 as compared to Visit 2. This 1.0 point difference in baseline-adjusted muscle soreness from two hours post-exercise to 48 hours post-exercise approached statistical significance (p=0.080), suggesting a dose-related improvement. Regarding fatigue, all subjects experienced an increase in fatigue that trended towards significance two hours post-exercise at the pre intervention visit (p = 0.084), whereas there was no trend at the post intervention visit (p = 0.181). At the pre intervention visit, subjects’ fatigue scores increased between two and 48 hours post-exercise, but not significantly (p = 0.470), whereas post intervention, subjects fatigue scores decreased between two and 48 hours post-exercise, but not significantly (p = 0.336).